IDiyas

For the Inventor, By the Inventor

Montpellier, France

Institut Regional Du Cancer De Montpellier


USPTO Granted Patents = 14



Forward Citations = 0

Loading Chart...
Loading Chart...

39 inventors (with patents filed for the assignee):

goldMedal Pierre Martineau (5 out of 8 patents)

silverMedal Bruno Robert (4 out of 7 patents)

bronzeMedal Alain Thierry (4 out of 4 patents)

4.  Myriam Chentouf (3 out of 4 patents)

5.  Safia El Messaoudi (3 out of 3 patents)

6.  Christel Larbouret (3 out of 9 patents)

7.  André Pelegrin (2 out of 7 patents)

8.  Thierry Chardes (2 out of 7 patents)

9.  Samir Hamamah (1 out of 15 patents)

10.  Said Assou (1 out of 7 patents)

11.  Thierry Chardès (1 out of 1 patent)

12.  Olivier Dubreuil (1 out of 3 patents)

13.  Jean-François Prost (1 out of 4 patents)

14.  Jean-Marc Barret (1 out of 9 patents)

15.  Stéphane Degove (1 out of 1 patent)


14 patents:

1. 12485126 - Combination for treating cancer (2025-12-02),
2. 12460009 - Monoclonal antibodies specific for IL20-Rb, encoding nucleic acids thereof and methods of use thereof to treat bacterial-induced exacerbation of chronic obstructive pulmonary disease (2025-11-04),
3. 12441788 - Anti-müllerian inhibiting substance antibodies and uses thereof (2025-10-14),
4. 11821044 - Methods for screening a subject for a cancer (2023-11-21),
5. 11814686 - Method for screening and treating a subject for a cancer (2023-11-14),
6. 11149314 - Methods for determining the quality of an embryo (2021-10-19),
7. 11001634 - Anti-human-HER3 antibodies and uses thereof (2021-05-11),
8. 10758615 - Human monoclonal antibodies against orexin receptor type 1 (2020-09-01),
9. 10704104 - Methods for screening a subject for a cancer (2020-07-07),
10. 10526415 - Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor (2020-01-07),
11. 10398774 - Human monoclonal antibodies against AXL (2019-09-03),
12. 10196455 - Neuregulin allosteric anti-HER3 antibody (2019-02-05),
13. 10001491 - Method for determining radiosensitivity (2018-06-19),
14. 9931416 - Anti-claudin 1 antibodies for use in the treatment of colorectal cancer (2018-04-03),
15. 9687552 - Association of poly(N-acryloylglycinamide) with at least one active principle (2017-06-27),
The INSTITUT REGIONAL DU CANCER DE MONTPELLIER (Regional Cancer Institute of Montpellier) is a leading medical institution dedicated to cancer diagnosis, treatment, and research. Our multidisciplinary team of specialists and researchers work collaboratively to provide state-of-the-art oncology care to patients. With a focus on personalized medicine, we strive to deliver tailored treatment plans that offer the best outcomes for each individual. Visit our website to learn more about our comprehensive services, ongoing research projects, and commitment to advancing cancer care.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

14 Patents

#8 in Montpellier

#1,287 in France

#40,857 in the World

...
Montpellier, France

Institut Regional Du Cancer De Montpellier

Forward Citations = 0

39 inventors:

goldMedal Pierre Martineau (5 out of 8 patents)

silverMedal Bruno Robert (4 out of 7 patents)

bronzeMedal Alain Thierry (4 out of 4 patents)

4.  Myriam Chentouf (3 out of 4 patents)

5.  Safia El Messaoudi (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com
Loading…